- Defence Therapeutics’ (DTC) AccuTOX compound has been shown to elicit cell death in cancer cells
- The company discovered the compound’s novel cell DNA damaging function which may serve to treat numerous cancers
- AccuTOX’s phase I trial in North America is forthcoming
- Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates
- Defence Therapeutics (DTC) is up by 15.56 per cent trading at $2.08 per share
Defence Therapeutics’ (DTC) AccuTOX compound has been shown to elicit cell death in cancer cells.
The mechanism of action involves a novel DNA damaging function triggered by the compound with potential applications across multiple cancers.
When combined with multiple immune-checkpoints, AccuTOX yields a survival rate between 60-100 per cent based on pre-clinical tumor model studies in mice.
Defence is conducting good laboratory practice (GLP) studies on AccuTOX prior to a phase I trial in North America.
“Defence’s breakthrough discovery with its AccuTOX formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with Accum,” stated Sébastien Plouffe, CEO of Defence Therapeutics.
“Discovering that AccuTOX can behave as a chemotherapeutic agent targeting the DNA of cancer cells and an immune-checkpoint inhibitor booster is a new discovery that is highly valuable to Defence’s pipeline and future potential developments,” he added.
Defence Therapeutics is a biotechnology company engineering the next generation of vaccines and antibody drug conjugates.
Defence Therapeutics (DTC) is up by 15.56 per cent trading at $2.08 per share as of 2:24 pm EST.
